Nanomedicine applied to translational oncology: A future perspective on cancer treatment

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 1, 2016, Pages 81-103

  Bregoli, Lisa ^a   Movia, Dania ^b   Gavigan Imedio, James D ^c   Lysaght, Joanne ^d   Reynolds, John ^d   Prina Mello, Adriele ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cancer therapeutics; Nanodrug design; Nanomedicine; Nanomedicine regulation; Translational oncology

Indexed keywords

DISEASES; DRUG INTERACTIONS; NANOTECHNOLOGY; ONCOLOGY;

ANTI-CANCER THERAPIES; CANCER THERAPEUTICS; CLINICAL APPLICATION; CLINICAL MANAGEMENT; CLINICAL TRANSLATION; CURRENT CAPABILITY; FUTURE PERSPECTIVES; THERAPEUTIC VALUES;

MEDICAL NANOTECHNOLOGY;

ALBUMIN; LIPOSOME; NANOMATERIAL; PROTEIN CORONA; NANOPARTICLE;

CANCER CELL; CANCER THERAPY; CLINICAL EVALUATION; HUMAN; INTERNALIZATION; MICELLE; NANOMEDICINE; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSLATIONAL ONCOLOGY; TUMOR VASCULARIZATION; ANIMAL; DRUG APPROVAL; FORECASTING; NEOPLASMS; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; DRUG APPROVAL; FORECASTING; HUMANS; MEDICAL ONCOLOGY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84957083169     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.08.006     Document Type: Review

References (171)

1. Morigi V., Tocchio A., Bellavite Pellegrini C., Sakamoto J.H., Arnone M., Tasciotti E. Nanotechnology in medicine: from inception to market domination. J Drug Deliv 2012, 2012. [PubMed PMID: 22506121. PMCID: 3312282].
2. White Paper to the Horizon 2020 Framework Programme for Research and Innovation - recommendations from the nanomedicine community Available from:. http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/etpn-white-paper-H2020.
3. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9(1):1-14. [PubMed PMID: 22684017].
4. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12(1):39-50. [PubMed PMID: 22193407].
5. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171. [PubMed PMID: 15738981].
6. Jain K.K. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine (Lond) 2009, 4(3):249-252. [PubMed PMID: 19331532].
7. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol Cells 2011, 31(4):295-302. [PubMed PMID: 21360197].
8. Sakamoto J.H., van de Ven A.L., Godin B., Blanco E., Serda R.E., Grattoni A., et al. Enabling individualized therapy through nanotechnology. Pharmacol Res 2010, 62(2):57-89. [PubMed PMID: 20045055. PMCID: 2886806].
9. Prabhu P., Patravale V. The upcoming field of theranostic nanomedicine: an overview. J Biomed Nanotechnol 2012, 8(6):859-882. [PubMed PMID: 23029995].
10. Melancon M.P., Stafford R.J., Li C. Challenges to effective cancer nanotheranostics. J Control Release 2012, 164(2):177-182. [PubMed PMID: 22906841. PMCID: 3504179].
11. Khorasani A.A., Weaver J.L., Salvador-Morales C. Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques. Int J Nanomedicine 2014, 9:5729-5751. [PubMed PMID: 25525356].
12. Bawa R. FDA and nanotech: baby steps lead to regulatory uncertainty. Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Sciences 2013, J. Wiley, L. Sons (Eds.).
13. Eaton M.A., Levy L., Fontaine O.M. Delivering nanomedicines to patients: a practical guide. Nanomedicine 2015, 11(4):983-992. [PubMed PMID: 25724929].
14. Villalonga-Barber C., Micha-Screttas M., Steele B.R., Georgopoulos A., Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties. Curr Top Med Chem 2008, 8(14):1294-1309. [PubMed PMID: 18855710].
15. Clift M.J., Stone V. Quantum dots: an insight and perspective of their biological interaction and how this relates to their relevance for clinical use. Theranostics 2012, 2(7):668-680. [PubMed PMID: 22896769. PMCID: 3418927].
16. Chow E.K., Zhang X.Q., Chen M., Lam R., Robinson E., Huang H., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 2011, 3(73):73ra21. [PubMed PMID: 21389265].
17. Partha R., Conyers J.L. Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine 2009, 4:261-275. [PubMed PMID: 20011243. PMCID: 2789438].
18. Klumpp C., Kostarelos K., Prato M., Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006, 1758(3):404-412. [PubMed PMID: 16307724].
19. Cai W., Gao T., Hong H., Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl 2008, 1:17-32. [PubMed PMID: 24198458. PMCID: 3781768].
20. Lal S., Clare S.E., Halas N.J. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res 2008, 41(12):1842-1851. [PubMed PMID: 19053240].
21. Sawant K.K., Dodiya S.S. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008, 2(2):120-135. [PubMed PMID: 19075903].
22. Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005, 2(4):369-381. [PubMed PMID: 16305440].
23. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303(5665):1818-1822. [PubMed PMID: 15031496].
24. Kim B.Y., Rutka J.T., Chan W.C. Nanomedicine. N Engl J Med 2010, 363(25):2434-2443. [PubMed PMID: 21158659].
25. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760. [PubMed PMID: 18654426].
26. Bakht M.K., Sadeghi M., Pourbaghi-Masouleh M., Tenreiro C. Scope of nanotechnology-based radiation therapy and thermotherapy methods in cancer treatment. Curr Cancer Drug Targets 2012, 12(8):998-1015. [PubMed PMID: 22809233].
27. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7(11):653-664. [PubMed PMID: 20838415. PMCID: Pmc3065247. Epub 2010/09/15. eng].
28. Movia D.P.C., Tran L., Volkov Y., Prina-Mello A. Multilayered nanoparticles for personalized medicine: translation into clinical markets. Handbook of Clinical Nanomedicine: From Bench to Bedside 2014, Pan Stanford Publishing.
29. Chauhan V.P., Jain R.K. Strategies for advancing cancer nanomedicine. Nat Mater 2013, 12(11):958-962. [PubMed PMID: 24150413].
30. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5(4):505-515. [PubMed PMID: 18672949. PMCID: 2663893].
31. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5(1):73-82. [PubMed PMID: 18829396. PMCID: 2824435].
32. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9(5):1909-1915. [PubMed PMID: 19344179. Epub 2009/04/07. eng].
33. Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013, 4:2516. [PubMed PMID: 24084631. PMCID: 3806395].
34. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6(12):815-823. [PubMed PMID: 22020122. Epub 2011/10/25. eng].
35. Stylianopoulos T., Poh M.Z., Insin N., Bawendi M.G., Fukumura D., Munn L.L., et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 2010, 99(5):1342-1349. [PubMed PMID: 20816045. PMCID: 2931749].
36. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7(6):383-388. [PubMed PMID: 22484912. PMCID: 3370066].
37. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-627. [PubMed PMID: 20616808].
38. Rajendran L., Knolker H.J., Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 2010, 9(1):29-42. [PubMed PMID: 20043027].
39. Huang J.G., Leshuk T., Gu F.X. Emerging nanomaterials for targeting subcellular organelles. Nano Today 2011, 6(5):478-492.
40. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.-P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29(24):3477-3496.
41. Zuhorn I.S., Engberts J.B., Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007, 36(4-5):349-362. [PubMed PMID: 17019592].
42. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35(18):5616-5623.
43. Howard K.A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev 2009, 61(9):710-720.
44. Shmueli R.B., Anderson D.G., Green J.J. Electrostatic surface modifications to improve gene delivery. Expert Opin Drug Deliv 2010, 7(4):535-550.
45. Lungwitz U., Breunig M., Blunk T., Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005, 60(2):247-266.
46. Walkey C.D., Chan W.C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 2012, 41(7):2780-2799.
47. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci 2008, 105(38):14265-14270.
48. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010, 5(6):e10949.
49. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4(7):3623-3632.
50. Wolfram J., Yang Y., Shen J., Moten A., Chen C., Shen H., et al. The nano-plasma interface: implications of the protein corona. Colloids Surf B: Biointerfaces 2014, 124:17-24.
51. Tenzer S., Docter D., Rosfa S., Wlodarski A., Kuharev, Rekik A., et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011, 5(9):7155-7167.
52. Hajipour M.J., Laurent S., Aghaie A., Rezaee F., Mahmoudi M. Personalized protein coronas: a "key" factor at the nanobiointerface. Biomater Sci 2014, 2:1210-1221. 10.1039/C4BM00131A.
53. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
54. Schäffler M., Sousa F., Wenk A., Sitia L., Hirn S., Schleh C., et al. Blood protein coating of gold nanoparticles as potential tool for organ targeting. Biomaterials 2014, 35(10):3455-3466.
55. Chen N., Li Y., Ye Y., Palmisano M., Chopra R., Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 2014, 54(10):1097-1107.
56. McKim J.M. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen 2010, 13(2):188-206.
57. Dawidczyk C.M., Kim C., Park J.H., Russell L.M., Lee K.H., Pomper M.G., et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 2014, 187:133-144. [PubMed PMID: 24874289. PMCID: 4132889].
58. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782. [PubMed PMID: 18758474].
59. Mansour H., Park C., Bawa R. Design and development of approved nanopharmaceutical products. Handbook of Clinical Nanomedicine: From Bench to Bedside 2014, Pan Stanford Publishing, Singapore, [Available May. 2014;31]. R. Bawa, G. Audette, I. Rubinstein (Eds.).
60. Zamboni W.C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11(23):8230-8234. [PubMed PMID: 16322279].
61. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42(5):419-436. [PubMed PMID: 12739982].
62. Sanna V., Pala N., Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 2014, 9:467-483. [PubMed PMID: 24531078. PMCID: 3896284].
63. Drugs, UFaDA FDA approved drug products. Online database Available from:. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
64. Tan S., Li X., Guo Y., Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale 2013, 5(3):860-872. [PubMed PMID: 23292080].
65. Waterhouse D.N., Tardi P.G., Mayer L.D., Bally M.B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001, 24(12):903-920. [PubMed PMID: 11735647].
66. Forssen E.A. The design and development of DaunoXome® for solid tumor targeting in vivo. Adv Drug Deliv Rev 1997, 24(2):133-150.
67. Advantages of liposomal delivery systems for anthracyclines. Seminars in oncology 2004, Elsevier. T.M. Allen, F.J. Martin (Eds.).
68. Fassas A., Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005, 46(6):795-802.
69. Wang R., Billone P.S., Mullett W.M. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013, 2013:1. Article ID 629681, 12 pages http://dx.doi.org/10.1155/2013/629681.
70. Phuphanich S., Maria B., Braeckman R., Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007, 81(2):201-208. [PubMed PMID: 16941075].
71. Angst M.S., Drover D.R. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 2006, 45(12):1153-1176. [PubMed PMID: 17112293].
72. FDA approves liposomal vincristine (Marqibo) for rare leukemia. Oncology (Williston Park) 2012, 26(9):841. [PubMed PMID: 23061340].
73. Silverman J.A., Deitcher S.R. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 2013, 71(3):555-564. [PubMed PMID: 23212117. PMCID: 3579462].
74. Nardin A., Lefebvre M.L., Labroquere K., Faure O., Abastado J.P. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006, 6(2):123-133. [PubMed PMID: 16529542].
75. Meyers P.A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009, 9(8):1035-1049. [PubMed PMID: 19671023].
76. Ando K., Mori K., Corradini N., Redini F., Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 2011, 12(2):285-292. [PubMed PMID: 21226638. PMCID: 3413631].
77. Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2006, 2(3):333-343. [PubMed PMID: 16787112].
78. Fogler W.E., Fidler I.J. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Int J Immunopharmacol 1987, 9(2):141-150. [PubMed PMID: 3583507].
79. Gay B., Cardot J.M., Schnell C., van Hoogevest P., Gygax D. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. J Pharm Sci 1993, 82(10):997-1001. [PubMed PMID: 8254500].
80. http://clinicaltrials.gov/ct2/home.
81. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803. [PubMed PMID: 16172456].
82. Tallal L., Tan C., Oettgen H., Wollner N., McCarthy M., Helson L., et al. E. colil-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970, 25(2):306-320. [PubMed PMID: 4905155].
83. Jarrar M., Gaynon P.S., Periclou A.P., Fu C., Harris R.E., Stram D., et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006, 47(2):141-146. [PubMed PMID: 16425271].
84. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12(5):601-609. [PubMed PMID: 17522249].
85. Hoggatt J., Pelus L.M. New G-CSF agonists for neutropenia therapy. Expert Opin Investig Drugs 2014, 23(1):21-35. [PubMed PMID: 24073859].
86. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14(1):29-35. [PubMed PMID: 12488289].
87. Hoggatt J., Tate T.A., Pelus L.M. Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. Int J Nanomedicine 2015, 10:2647-2652. [PubMed PMID: 25878498. PMCID: 4388090].
88. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27(12):2569-2589. [PubMed PMID: 20725771. PMCID: 2982955].
89. Hildebrandt B., Wust P., Ahlers O., Dieing A., Sreenivasa G., Kerner T., et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002, 43(1):33-56. [PubMed PMID: 12098606].
90. Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002, 3(8):487-497. [PubMed PMID: 12147435].
91. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161(2):175-187. [PubMed PMID: 21945285].
92. Borsi L., Balza E., Bestagno M., Castellani P., Carnemolla B., Biro A., et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102(1):75-85. [PubMed PMID: 12353237].
93. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279(5349):377-380. [PubMed PMID: 9430587].
94. Ding Y., Li S., Nie G. Nanotechnological strategies for therapeutic targeting of tumor vasculature. Nanomedicine (Lond) 2013, 8(7):1209-1222. [PubMed PMID: 23837858].
95. Huang S., Shao K., Liu Y., Kuang Y., Li J., An S., et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013, 7(3):2860-2871. [PubMed PMID: 23451830].
96. Xie J., Shen Z., Li K.C., Danthi N. Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle. Int J Nanomedicine 2007, 2(3):479-485. [PubMed PMID: 18019845. PMCID: 2676654].
97. Danhier F., Vroman B., Lecouturier N., Crokart N., Pourcelle V., Freichels H., et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 2009, 140(2):166-173. [PubMed PMID: 19699245].
98. Dubey P.K., Singodia D., Verma R.K., Vyas S.P. RGD modified albumin nanospheres for tumour vasculature targeting. J Pharm Pharmacol 2011, 63(1):33-40. [PubMed PMID: 21155813].
99. Tinkle S., McNeil S.E., Muhlebach S., Bawa R., Borchard G., Barenholz Y.C., et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci 2014, 1313:35-56. [PubMed PMID: 24673240].
100. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16(24):6139-6149. [PubMed PMID: 20876255. PMCID: 3004980].
101. http://www.cytimmune.com.
102. Schmitt-Sody M., Strieth S., Krasnici S., Sauer B., Schulze B., Teifel M., et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003, 9(6):2335-2341. [PubMed PMID: 12796403].
103. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Investig 1998, 101(7):1401.
104. Löhr M., Bodoky G., Fölsch U., Märten A., Karrasch M., Lilla C., et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial. Ann Oncol 2012 May, 23(5):1214-1222. 10.1093/annonc/mdr379.
105. Awada A., Bondarenko I., Tarasova O., Bonneterre J., Nowara E., Ferrero J., et al. Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 2014 Apr, 25(4):824-831. 10.1093/annonc/mdu025.
106. Ribeiro J.T., Macedo L.T., Curigliano G., Fumagalli L., Locatelli M., Dalton M., et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. Ann Oncol 2012, 23(3):547-555. [PubMed PMID: 21896541].
107. http://www.medigene.com.
108. O'Brien M.E., Socinski M.A., Popovich A.Y., Bondarenko I.N., Tomova A., Bilynsky B.T., et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(7):728-734.
109. Sabbatini P., Sill M.W., O'Malley D., Adler L., Secord A.A. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol 2008, 111(3):455-460.
110. Lin N.U., Parker L.M., Come S.E., Burstein H.J., Haldoupis M., Ryabin N., et al. Phase II study of CT-2103 as first-or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Investig New Drugs 2007, 25(4):369-375.
111. Treat J., Damjanov N., Huang C., Zrada S., Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park) 2001, 15(5 Suppl. 7):44-48.
112. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999, 43(1):1-7. [English].
113. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077 TM) in patients with inoperable head and neck cancer. Ann Oncol 2001, 12(4):493-496.
114. Seetharamu N., Kim E., Hochster H., Martin F., Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010, 30(2):541-545.
115. White S.C., Lorigan P., Margison G.P., Margison J.M., Martin F., Thatcher N., et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006, 95(7):822-828. [PubMed PMID: 16969346. PMCID: 2360546].
116. Veal G.J., Griffin M.J., Price E., Parry A., Dick G.S., Little M.A., et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001, 84(8):1029-1035. [PubMed PMID: 11308249. PMCID: 2363870].
117. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001, 12(4):493-496. [PubMed PMID: 11398881].
118. Kim E.S., Lu C., Khuri F.R., Tonda M., Glisson B.S., Liu D., et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001, 34(3):427-432. [PubMed PMID: 11714540].
119. Rosenthal D.I., Yom S.S., Liu L., Machtay M., Algazy K., Weber R.S., et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002, 20(3):343-349. [PubMed PMID: 12201498].
120. Vokes E.E., Gordon G.S., Mauer A.M., Rudin C.M., Krauss S.A., Szeto L., et al. A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer 2000, 2(2):128-132. [PubMed PMID: 14731323].
121. Oberoi H.S., Nukolova N.V., Kabanov A.V., Bronich T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013, 65(0):1667-1685. [PubMed PMID: PMC4197009].
122. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 2011, 29(5):1029-1037. [PubMed PMID: 20179989].
123. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91(10):1775-1781. [PubMed PMID: 15477860. PMCID: 2410050].
124. Endo K., Ueno T., Kondo S., Wakisaka N., Murono S., Ito M., et al. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci 2013, 104(3):369-374. [PubMed PMID: 23216802].
125. Weiss G.J., Chao J., Neidhart J.D., Ramanathan R.K., Bassett D., Neidhart J.A., et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013, 31(4):986-1000. [PubMed PMID: 23397498. PMCID: 3774600].
126. Kono K., Nakashima S., Kokuryo D., Aoki I., Shimomoto H., Aoshima S., et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 2011, 32(5):1387-1395. [PubMed PMID: 21093041].
127. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009, 10(2):333-343. [PubMed PMID: 19236203].
128. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007, 13(9):2722-2727. [PubMed PMID: 17473205. PMCID: 2555974].
129. Johannsen M., Thiesen B., Wust P., Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia 2010, 26(8):790-795. [PubMed PMID: 20653418].
130. Dennis C.L., Jackson A.J., Borchers J.A., Hoopes P.J., Strawbridge R., Foreman A.R., et al. Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology 2009, 20(39):395103. [PubMed PMID: 19726837].
131. Gad S.C., Sharp K.L., Montgomery C., Payne J.D., Goodrich G.P. Evaluation of the toxicity of intravenous delivery of Auroshell particles (gold-silica nanoshells). Int J Toxicol 2012, 31(6):584-594. [PubMed PMID: 23212452].
132. Schwartz J.A., Shetty A.M., Price R.E., Stafford R.J., Wang J.C., Uthamanthil R.K., et al. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res 2009, 69(4):1659-1667. [PubMed PMID: 19208847].
133. Rivera Gil P., Huhn D., del Mercato L.L., Sasse D., Parak W.J. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds. Pharmacol Res 2010, 62(2):115-125. [PubMed PMID: 20097288].
134. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44(10):1123-1134. [PubMed PMID: 21692448].
135. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54(4):561-587. [PubMed PMID: 12429868].
136. Wang S., Low P.S. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release 1998, 53(1-3):39-48. [PubMed PMID: 9741912].
137. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070. [PubMed PMID: 20305636. PMCID: 2855406].
138. Zuckerman J.E., Gritli I., Tolcher A., Heidel J.D., Lim D., Morgan R., et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci 2014, 111(31):11449-11454.
139. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008, 105(7):2586-2591. PubMed PMID: 18272481. PMCID: 2268180.
140. Venditto V.J., Szoka F.C. Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013, 65(1):80-88.
141. Valencia P.M., Farokhzad O.C., Karnik R., Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol 2012, 7(10):623-629. [PubMed PMID: 23042546. PMCID: 3654404].
142. Ehmann F., Sakai-Kato K., Duncan R., Hernan Perez de la Ossa D., Pita R., Vidal J.M., et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) 2013, 8(5):849-856. [PubMed PMID: 23656268].
143. Nystrom A.M., Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J Control Release 2012, 161(2):403-408. [PubMed PMID: 22306428].
144. Fadeel B., Garcia-Bennett A.E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010, 62(3):362-374. [PubMed PMID: 19900497].
145. Murday J.S., Siegel R.W., Stein J., Wright J.F. Translational nanomedicine: status assessment and opportunities. Nanomedicine 2009, 5(3):251-273. [PubMed PMID: 19540359].
146. Stone V., Johnston H., Schins R.P. Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 2009, 39(7):613-626. [PubMed PMID: 19650720].
147. Cho E.C., Zhang Q., Xia Y. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat Nanotechnol 2011, 6(6):385-391. [PubMed PMID: 21516092. PMCID: 3227810. Epub 2011/04/26. eng].
148. Napierska D., Thomassen L.C., Lison D., Martens J.A., Hoet P.H. The nanosilica hazard: another variable entity. Part Fibre Toxicol 2010 Dec 3, 7(1):39. 10.1186/1743-8977-7-39.
149. Vinci M., Gowan S., Boxall F., Patterson L., Zimmermann M., Court W., et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012, 10:29. [PubMed PMID: 22439642. PMCID: 3349530. Epub 2012/03/24. eng].
150. Nyga A., Cheema U., Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 2011, 5(3):239-248. [PubMed PMID: 21499821. PMCID: 3145874. Epub 2011/04/19. eng].
151. Cho E.J., Holback H., Liu K.C., Abouelmagd S.A., Park J., Yeo Y. Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm 2013, 10(6):2093-2110. [PubMed PMID: 23461379. PMCID: 3672343].
152. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8(7):543-557. [PubMed PMID: 19525947].
153. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012, 14(2):282-295. [English].
154. Stern S.T., Hall J.B., Yu L.L., Wood L.J., Paciotti G.F., Tamarkin L., et al. Translational considerations for cancer nanomedicine. J Control Release 2010, 146(2):164-174.
155. Hoet P., Legiest B., Geys J., Nemery B. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?. Drug Saf 2009, 32(8):625-636. [PubMed PMID: 19591528].
156. Crist R.M., Grossman J.H., Patri A.K., Stern S.T., Dobrovolskaia M.A., Adiseshaiah P.P., et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol 2013, 5(1):66-73.
157. Muthu M.S., Wilson B. Challenges posed by the scale-up of nanomedicines. Nanomedicine 2012, 7(3):307-309.
158. Draft Guidance for Industry Considering whether an FDA regulated product involves the application of nanotechnology 2011 Available from:. http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm.
159. Commission Recommendation of 18 October 2011 on the definition of nanomaterial Available from:. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:275:0038:0040:EN:PDF.
160. Scientific Committee on Emerging and Newly Identified Health Risks Scientific basis for the definition of the term "nanomaterial" Available from:. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_030.pdf.
161. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005, 11(11):4136-4143. [PubMed PMID: 15930349].
162. Commission E Proposal for a regulation of the European Parliament and of the Council on medical devices, and amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 Available from:. http://ec.europa.eu/health/medical-devices/files/revision_docs/proposal_2012_542_en.pdf.
163. Hafner A., Lovrić J., Lakoš G.P., Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine 2014 Feb 19, 9:1005-1023. 10.2147/IJN.S55359. eCollection 2014.
164. Administration UFaD Nanotechnology: a report of the US Food and Drug Administration, Nanotechnology Task Force 2007, US Food and Drug Administration, Rockville, MD.
165. Food U., Administration D. Draft guidance for industry: considering whether an FDA-regulated product involves the application of nanotechnology 2011, US FDA.
166. Hamburg M.A. FDA's approach to regulation of products of nanotechnology. Science 2012, 336(6079):299-300.
167. Milmo S. Seeking harmonization in nanomedicines regulatory framework. BioPharm Int 2013, 26(8):12-13.
168. Dorbeck-Jung B.R.C.N. Is the European medical products authorisation regulation equipped to cope with the challenges of nanomedicines?. Law Policy 2011, 3(2):276-303.
169. van Calster Geert Regulating nanotechnology in the European Union Nanotechnology. Law Bus 2006, 3(3):359-372.
170. Toma-Bianov A. European Union regulations on nanomedicine. Bulletin of the Transylvania University of Braşov Series VII: Social Sciences 2012, 5 (54). [2].
171. D'Silva J., Calster Gv. Taking temperature - a review of European Union regulation in nanomedicine. Eur J Health Law 2009, 16:249-269.